BioAtla, Inc. (NASDAQ:BCAB) Stock Position Lowered by Two Sigma Advisers LP

Two Sigma Advisers LP trimmed its position in shares of BioAtla, Inc. (NASDAQ:BCAB) by 33.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 61,500 shares of the company’s stock after selling 30,546 shares during the period. Two Sigma Advisers LP owned 0.13% of BioAtla worth $36,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Two Sigma Investments LP lifted its holdings in shares of BioAtla by 84.0% in the fourth quarter. Two Sigma Investments LP now owns 135,177 shares of the company’s stock valued at $80,000 after purchasing an additional 61,725 shares in the last quarter. Jane Street Group LLC lifted its stake in BioAtla by 204.1% in the 4th quarter. Jane Street Group LLC now owns 149,291 shares of the company’s stock worth $88,000 after acquiring an additional 100,204 shares in the last quarter. Norges Bank purchased a new stake in BioAtla in the 4th quarter worth about $230,000. Jacobs Levy Equity Management Inc. acquired a new stake in BioAtla during the 4th quarter worth about $383,000. Finally, Boxer Capital Management LLC purchased a new position in BioAtla during the 4th quarter valued at about $406,000. 77.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Wall Street Zen upgraded BioAtla from a “sell” rating to a “hold” rating in a report on Friday. HC Wainwright reiterated a “neutral” rating on shares of BioAtla in a research note on Monday, March 31st.

BioAtla Trading Up 5.5%

Shares of NASDAQ:BCAB opened at $0.48 on Monday. The firm has a market cap of $28.15 million, a price-to-earnings ratio of -0.28 and a beta of 0.92. BioAtla, Inc. has a 1 year low of $0.24 and a 1 year high of $2.53. The business has a fifty day simple moving average of $0.40 and a 200 day simple moving average of $0.58.

BioAtla (NASDAQ:BCAB) last issued its earnings results on Tuesday, May 6th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.01). On average, sell-side analysts forecast that BioAtla, Inc. will post -1.46 EPS for the current year.

BioAtla Company Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.